SCHEMBL294156

SCHEMBL294156

O=S(=O)(Nc1nnc(C2CCCCC2)s1)c1ccc2c(c1)CC(Nc1ncc(C(F)(F)F)cc1Cl)C2

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.45
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HCRTR1 O43613 3/20 0.37
POLB P06746 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
SCN9A Q15858 7/20 0.36
MAPT P10636 2/20 0.34
XBP1 P17861 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
SCN5A Q14524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL293567 0.96 KMT2A (0.45) KMT2AMEN1ALDH1A1HSD17B10TDP1
SCHEMBL294734 0.87 MEN1 (0.50) KMT2AMEN1ALDH1A1TDP1POLB
SCHEMBL295244 0.84 KMT2A (0.47) KMT2AMEN1ALDH1A1TDP1HCRTR1
SCHEMBL295358 0.84 MEN1 (0.46) KMT2AMEN1ALDH1A1HSD17B10TDP1
SCHEMBL2772880 0.77 MEN1 (0.48) KMT2AMEN1ALDH1A1TDP1HCRTR1
SCHEMBL13763850 0.76 KMT2A (0.49) KMT2AMEN1ALDH1A1HSD17B10POLB
SCHEMBL295829 0.74 KMT2A (0.51) KMT2AMEN1ALDH1A1TDP1HCRTR1
SCHEMBL295828 0.74 KMT2A (0.51) KMT2AMEN1ALDH1A1TDP1HCRTR1
SCHEMBL1972903 0.74 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1HSD17B10POLB
SCHEMBL294845 0.73 POLB (0.42) KMT2AMEN1ALDH1A1HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344004-B2 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2013-01-01 US disclosed
US-8344004-B2 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2013-01-01 US disclosed
EP-2240474-B1 CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-03-14 EP disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals PPARD, PPARG, PPARA KMT2A 3682/4885MEN1 4666/4885ALDH1A1 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.